Seattle Genetics to Host Conference Call and Webcast on September 27, 2010 Regarding Top-line Data from Brentuximab Vedotin (SGN-35) Pivotal Hodgkin Lymphoma Clinical Trial

SEATTLE--(BUSINESS WIRE)--Sep 24, 2010 - Seattle Genetics, Inc. (Nasdaq: SGEN) today announced that its management will host a conference call and webcast on Monday, September 27, 2010, at 5:30 a.m. Pacific Time (PT) / 8:30 a.m. Eastern Time (ET) regarding top-line results from its brentuximab vedotin (SGN-35) pivotal clinical trial in Hodgkin lymphoma.

The live event will be available from Seattle Genetics' website at www.seattlegenetics.com, under the Investors and News section, or by calling (877) 941-8631 (domestic) or (480) 629-9819 (international). The access code is 4369251. A replay of the discussion will be available beginning at approximately 7:00 a.m. PT / 10:00 a.m. ET on September 27, 2010 from Seattle Genetics' website or by calling (800) 406-7325 (domestic) or (303) 590-3030 (international), using access code 4369251. The replay will be available through October 1, 2010.

About Seattle Genetics

Seattle Genetics is a clinical-stage biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer and autoimmune disease. The company's lead product candidate, brentuximab vedotin (SGN-35), is in a pivotal trial under a Special Protocol Assessment with the U.S. Food and Drug Administration. Brentuximab vedotin is being developed in collaboration with Millennium: The Takeda Oncology Company. In addition, Seattle Genetics has four other clinical-stage programs: SGN-75, ASG-5ME, dacetuzumab (SGN-40) and SGN-70. Seattle Genetics has collaborations for its ADC technology with a number of leading biotechnology and pharmaceutical companies, including Bayer, Celldex Therapeutics, Daiichi Sankyo, Genentech, GlaxoSmithKline, MedImmune, a subsidiary of AstraZeneca, Millennium: The Takeda Oncology Company and Progenics, as well as ADC co-development agreements with Agensys, an affiliate of Astellas, and Genmab. More information can be found at www.seattlegenetics.com.

 

Contact: Seattle Genetics, Inc.
Peggy Pinkston, 425-527-4160
ppinkston@seagen.com

 

Posted: September 2010

View comments

Hide
(web1)